See more : OHB SE (OHB.DE) Income Statement Analysis – Financial Results
Complete financial analysis of DexCom, Inc. (DXCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DexCom, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- OPRO CO LTD (228A.T) Income Statement Analysis – Financial Results
- Gannett Co., Inc. (GCI) Income Statement Analysis – Financial Results
- Evolution Technology Resources Inc. (ETKR) Income Statement Analysis – Financial Results
- Rich Universe Network Limited (RICHUNV.BO) Income Statement Analysis – Financial Results
- Huikwang Corporation (6508.TWO) Income Statement Analysis – Financial Results
DexCom, Inc. (DXCM)
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.62B | 2.91B | 2.45B | 1.93B | 1.48B | 1.03B | 718.50M | 573.30M | 402.00M | 259.20M | 160.00M | 99.90M | 76.27M | 48.63M | 29.69M | 9.84M | 4.63M | 2.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.33B | 1.03B | 768.00M | 646.60M | 544.50M | 367.70M | 226.40M | 194.90M | 123.60M | 82.90M | 59.90M | 53.30M | 40.42M | 30.19M | 26.03M | 15.37M | 12.74M | 10.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.29B | 1.88B | 1.68B | 1.28B | 931.50M | 663.90M | 492.10M | 378.40M | 278.40M | 176.30M | 100.10M | 46.60M | 35.84M | 18.44M | 3.66M | -5.53M | -8.11M | -8.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 63.19% | 64.72% | 68.63% | 66.44% | 63.11% | 64.36% | 68.49% | 66.00% | 69.25% | 68.02% | 62.56% | 46.65% | 47.00% | 37.92% | 12.33% | -56.20% | -175.25% | -405.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 505.80M | 484.20M | 604.20M | 359.90M | 273.50M | 417.40M | 185.40M | 156.10M | 137.50M | 69.40M | 44.80M | 39.50M | 30.75M | 23.23M | 14.29M | 19.63M | 16.13M | 19.42M | 26.77M | 12.47M | 8.93M | 6.31M | 5.04M | 2.90M |
| General & Administrative | 1.00B | 867.20M | 684.10M | 544.20M | 482.60M | 408.80M | 327.30M | 274.30M | 194.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 180.80M | 133.00M | 126.40M | 76.50M | 33.10M | 24.00M | 21.90M | 11.90M | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 325.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.19B | 1.00B | 810.50M | 620.70M | 515.70M | 432.80M | 349.20M | 286.20M | 198.00M | 128.40M | 84.20M | 62.80M | 49.94M | 40.51M | 35.20M | 27.67M | 22.44M | 21.11M | 5.66M | 1.60M | 1.25M | 0.00 | 1.69M | 1.11M |
| Other Expenses | 0.00 | 7.50M | -1.70M | 0.00 | 0.00 | 0.00 | 3.40M | -700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.69B | 1.49B | 1.41B | 980.60M | 789.20M | 850.20M | 534.60M | 442.30M | 335.50M | 197.80M | 129.00M | 102.30M | 80.69M | 63.73M | 49.49M | 47.30M | 38.57M | 40.53M | 32.43M | 14.07M | 10.18M | 6.31M | 6.72M | 4.01M |
| Cost & Expenses | 3.02B | 2.52B | 2.18B | 1.63B | 1.33B | 1.22B | 761.00M | 637.20M | 459.10M | 280.70M | 188.90M | 155.60M | 121.11M | 93.92M | 75.53M | 62.67M | 51.30M | 51.49M | 32.43M | 14.07M | 10.18M | 6.31M | 6.72M | 4.01M |
| Interest Income | 135.00M | 18.00M | 1.70M | 16.10M | 26.40M | 2.40M | 3.30M | 400.00K | 0.00 | 0.00 | 0.00 | 100.00K | 107.00K | 95.00K | 354.00K | 1.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 20.30M | 18.60M | 102.00M | 84.70M | 60.30M | 22.70M | 12.80M | 700.00K | 400.00K | 800.00K | 900.00K | 200.00K | 11.00K | 1.55M | 8.05M | 7.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 186.00M | 155.90M | 101.90M | 67.10M | 48.70M | 29.10M | 16.10M | 15.00M | 10.80M | 8.40M | 7.00M | 6.60M | 3.76M | 2.44M | 2.37M | 3.58M | 3.33M | 2.70M | 1.07M | 935.49K | 353.55K | 0.00 | 0.00 | 0.00 |
| EBITDA | 916.70M | 565.30M | 377.50M | 376.80M | 213.20M | -74.70M | -19.70M | -49.20M | -46.30M | -13.10M | -21.90M | -49.00M | -40.98M | -51.19M | -43.11M | -49.79M | -43.34M | -46.62M | -29.70M | -13.13M | -9.83M | -6.31M | -6.72M | -4.01M |
| EBITDA Ratio | 25.31% | 14.33% | 11.33% | 19.86% | 11.14% | -10.06% | -4.98% | -11.20% | -14.20% | -8.29% | -13.69% | -49.05% | -53.87% | -70.79% | -146.36% | -500.90% | -936.76% | -2,148.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 597.70M | 391.20M | 175.40M | 299.50M | 142.30M | -186.30M | -42.50M | -63.90M | -57.10M | -21.50M | -28.90M | -55.70M | -44.84M | -45.29M | -45.83M | -52.83M | -46.68M | -49.32M | -32.43M | -14.07M | -10.18M | -6.31M | -6.72M | -4.01M |
| Operating Income Ratio | 16.50% | 13.44% | 7.16% | 15.54% | 9.64% | -18.06% | -5.92% | -11.15% | -14.20% | -8.29% | -18.06% | -55.76% | -58.80% | -93.13% | -154.36% | -536.97% | -1,008.77% | -2,273.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 112.70M | -400.00K | -9.00M | -74.50M | -38.10M | 59.80M | -6.10M | -1.00M | -400.00K | -800.00K | -900.00K | -100.00K | 97.00K | -9.88M | -7.69M | -2.36M | 798.00K | 2.72M | -30.86B | 120.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 710.40M | 390.80M | 173.90M | 225.00M | 104.20M | -126.50M | -48.60M | -64.90M | -57.50M | -22.30M | -29.80M | -55.80M | -44.75M | -55.17M | -53.52M | -55.18M | -45.88M | -46.60M | -30.89B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 19.61% | 13.43% | 7.10% | 11.68% | 7.06% | -12.26% | -6.76% | -11.32% | -14.30% | -8.60% | -18.63% | -55.86% | -58.67% | -113.45% | -180.26% | -560.93% | -991.53% | -2,147.63% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 168.90M | 49.60M | 19.20M | -268.60M | 3.10M | 600.00K | 1.60M | 700.00K | 100.00K | 100.00K | 0.00 | -1.30M | -97.00K | 9.88M | 0.00 | 2.36M | 0.00 | 253.00 | -30.86B | -120.65K | -270.00K | 7.71M | 6.27M | 3.97M |
| Net Income | 541.50M | 341.20M | 154.70M | 493.60M | 101.10M | -127.10M | -50.20M | -65.60M | -57.60M | -22.40M | -29.80M | -54.50M | -44.75M | -55.17M | -53.52M | -55.18M | -45.88M | -46.60M | -30.77M | -13.95M | -9.91M | -7.71M | -6.27M | -3.97M |
| Net Income Ratio | 14.95% | 11.73% | 6.32% | 25.62% | 6.85% | -12.32% | -6.99% | -11.44% | -14.33% | -8.64% | -18.63% | -54.55% | -58.67% | -113.45% | -180.26% | -560.93% | -991.53% | -2,147.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 1.44 | 0.88 | 0.40 | 1.31 | 0.28 | -0.36 | -0.15 | -0.20 | -0.18 | -0.07 | -0.10 | -0.20 | -0.17 | -0.24 | -0.30 | -0.47 | -0.41 | -0.43 | -0.41 | -1.53 | -1.14 | -0.94 | -0.83 | -0.57 |
| EPS Diluted | 1.30 | 0.80 | 0.36 | 1.27 | 0.27 | -0.36 | -0.15 | -0.20 | -0.18 | -0.07 | -0.10 | -0.20 | -0.17 | -0.24 | -0.30 | -0.47 | -0.41 | -0.43 | -0.41 | -1.53 | -1.14 | -0.94 | -0.83 | -0.57 |
| Weighted Avg Shares Out | 386.00M | 389.40M | 386.90M | 377.60M | 364.40M | 352.80M | 345.20M | 334.40M | 319.20M | 300.80M | 284.40M | 274.80M | 262.40M | 227.60M | 177.39M | 117.95M | 113.25M | 108.94M | 75.78M | 9.14M | 8.68M | 8.18M | 7.59M | 6.91M |
| Weighted Avg Shares Out (Dil) | 425.50M | 427.50M | 428.80M | 390.00M | 369.20M | 352.80M | 345.20M | 334.40M | 319.20M | 300.80M | 284.40M | 274.80M | 262.40M | 227.60M | 177.39M | 117.95M | 113.25M | 108.94M | 75.78M | 9.14M | 8.68M | 8.18M | 7.59M | 6.91M |
11 Ultra SWAN Bargains That Could Thrive As The Market Soars To Record Highs
The S&P is up 27% in 2024, including a 5.5% rally in November. The Euphoria index is at record highs, indicating investor sentiment is extremely bullish. While 2025 is likely to see much larger volatility, there are still many excellent...
3 Reasons to Buy DexCom Stock Like There's No Tomorrow
Medical device specialist DexCom (DXCM -0.14%) is going through a rough patch. The company's shares are down sharply year to date due to unimpressive financial results -- and some of the headwinds it has encountered are, no doubt, concerning.
2 Excellent Healthcare Stocks to Hold Through the Next Decade
Although excellent medical care is always in high demand, the healthcare sector continuously evolves. Companies aren't automatically worth investing in just because they provide essential medical services.
Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over
The Nasdaq-100 index tracks the largest 100 non-financial companies on the Nasdaq stock exchange. Although it's not a part of the U.S. stock market's big three indexes ( S&P 500 , Nasdaq Composite, and Dow Jones), the Nasdaq-100 has grown in...
2 Superior Growth Stocks to Buy Right Now If You have $1,000 to Invest
It's not always easy to be a long-term investor, particularly when contending with the natural cyclicality that the stock market presents if you buy and hold through bull as well as bear markets.
DexCom and OURA Ink Partnership for Metabolic Health Innovation
DXCM and smart ring maker, OURA, join forces to help individuals make informed decisions regarding diet, exercise and overall well-being.
DexCom Pairs Its Glucose Monitor With Oura's Smart Ring
If you want to monitor your vital signs like an Olympic athlete, you should welcome a pact between glucose-monitor vendor DexCom and Oura smart rings.
Oura CEO on new partnership with Dexcom
Tom Hale, Oura CEO, joins 'Squawk Box' to discuss the company's new partnership with Dexcom, glucose monitors, and much more.
Smart ring maker Ōura valued at over $5 bln after Dexcom funding
Medical device maker Dexcom said on Tuesday it will invest $75 million in Ōura's latest funding round, valuing the smart ring maker at over $5 billion.
Source: https://incomestatements.info
Category: Stock Reports